(Q81223521)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15629355%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

title

Intranasal immunisation using recombinant Lactobacillus johnsonii as a new strategy to prevent allergic disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15629355%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

main subject

Lactobacillus johnsonii

object named as

Lactobacillus johnsonii

1 reference

Lorenz Scheppler

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15629355%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Monique Vogel

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15629355%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Pamela Marti

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15629355%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Lorenz Müller

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15629355%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Sylvia M Miescher

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15629355%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Beda M Stadler

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15629355%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

publication date

1 January 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15629355%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15629355%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15629355%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15629355%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

page(s)

1126-1134

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15629355%20AND%20SRC:MED&resulttype=core&format=json

The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics

6 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.031

The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.031

The role of anti-IgE therapies in the treatment of asthma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.031

Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.031

Omalizumab improves asthma-related quality of life in patients with severe allergic asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.031

Omalizumab improves asthma-related quality of life in children with allergic asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.031

Human IgE synthesis in vitro. Detection with monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.031

Searching for Peptide Ligands with an Epitope Library

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.031

Assembly of combinatorial antibody libraries on phage surfaces: the gene III site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.031

Mimicry of human IgE epitopes by anti-idiotypic antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.031

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.031

Expression of the protective antigen of Bacillus anthracis by Lactobacillus casei: towards the development of an oral vaccine against anthrax.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.031

Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.031

Engineering the microflora to vaccinate the mucosa: serum immunoglobulin G responses and activated draining cervical lymph nodes following mucosal application of tetanus toxin fragment C-expressing lactobacilli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.031

Instruments for oral disease-intervention strategies: recombinant Lactobacillus casei expressing tetanus toxin fragment C for vaccination or myelin proteins for oral tolerance induction in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.031

A new cell surface proteinase: sequencing and analysis of the prtB gene from Lactobacillus delbruekii subsp. bulgaricus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.031

Recombinant Lactobacillus johnsonii as a mucosal vaccine delivery vehicle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.031

Conformational stability, folding, and ligand-binding affinity of single-chain Fv immunoglobulin fragments expressed in Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.031

3 Protein engineering of single-chain Fv analogs and fusion proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.031

Non-repetitive single-chain Fv linkers selected by selectively infective phage (SIP) technology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.031

Selection of linkers for a catalytic single-chain antibody using phage display technology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.031

A recombinant immunotoxin containing a disulfide-stabilized Fv fragment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.031

Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.031

Stability engineering of antibody single-chain Fv fragments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.031

Optimizing the stability of single-chain proteins by linker length and composition mutagenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.031

Surface display of a functional single-chain Fv antibody on staphylococci.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.031

In situ delivery of passive immunity by lactobacilli producing single-chain antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.031

Oral anti-IgE immunization with epitope-displaying phage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.031

Resident aerobic microbiota of the adult human nasal cavityNote

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.031

A putative enzyme from various secretions specifically inhibits antibody-antigen interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.031

Mimotope and anti-idiotypic vaccines to induce an anti-IgE response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.031

Use of the Escherichia coli beta-glucuronidase (gusA) gene as a reporter gene for analyzing promoters in lactic acid bacteria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.031

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2004.08.031

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15629355%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1 reference